Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
STOCKHOLM, May 8, 2024 /PRNewswire/ -- Sobi® today announced that the European Commission (EC) has approved an indication extension for Aspaveli® (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
- STOCKHOLM, May 8, 2024 /PRNewswire/ -- Sobi® today announced that the European Commission (EC) has approved an indication extension for Aspaveli® (pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
- Aspaveli is already approved in Europe for the treatment of adults with PNH who are anaemic after treatment with a C5 inhibitor for at least three months.
- Aspaveli is now the first C3 inhibitor approved for first-line treatment of PNH in Europe, offering effective outcomes by improving haemoglobin and other clinical markers due to its unique mode of action.
- "European patients will now be able to initiate treatment with Aspaveli at diagnosis or switch from their current C5 inhibitor treatment if they present indicators of haemolytic anaemia.